At a Glance
- Context Therapeutics CEO Martin Lehr will present at the Jefferies Global Healthcare Conference.
- The presentation will cover the company's oncology pipeline and clinical development programs.
- Key programs ONC-392 and CTX-177 for various cancers will be highlighted.
Context Therapeutics Inc., a biopharmaceutical company dedicated to advancing new medicines for women's cancers, has announced its participation in the Jefferies Global Healthcare Conference. Martin Lehr, the company's Chief Executive Officer, is scheduled to present a corporate overview during a fireside chat. This event will take place on Wednesday, June 5, 2026, at 10:30 AM ET, offering insights into the company's strategic direction and clinical initiatives.
Advancing Oncology Programs
Mr. Lehr's discussion will focus on the company's current pipeline and ongoing clinical development programs. This includes updates on therapeutic candidates aimed at various forms of cancer. Investors and attendees can expect a detailed review of Context Therapeutics' progress in women's oncology.
One key program is ONC-392, an anti-CTLA-4 antibody. This candidate is currently in clinical development specifically for advanced gynecological cancers. The company is positioning ONC-392 as a potential new treatment option within this area of significant medical need.
Another significant candidate is CTX-177, a novel Claudin 6 (CLDN6) x CD3 bispecific antibody. CTX-177 is being developed for solid tumors, including ovarian cancer and testicular cancer. This bispecific antibody represents an approach to targeting specific cancer cells.
Context Therapeutics maintains a focused mission on the discovery and development of novel treatments for women's cancers. Its strategic efforts are directed towards addressing critical unmet needs in these patient populations. The company aims to bring forward new therapeutic options that can improve patient outcomes.
"Mr. Lehr will participate in a fireside chat during the conference, discussing Context Therapeutics’ pipeline and clinical development programs."
— Martin Lehr, Chief Executive Officer at Context Therapeutics Inc.
Engaging the Investment Community
The Jefferies Global Healthcare Conference serves as an important forum for biopharmaceutical companies to connect with the investment community. Context Therapeutics' participation underscores its commitment to transparency regarding its scientific progress and corporate strategy. Such events are vital for communicating value to stakeholders.
For those unable to attend in person, a live webcast of the fireside chat will be accessible. This webcast will be available via the "Events & Presentations" section of the Context Therapeutics website. An archived replay will also be provided on the site for a limited period following the live event.
The company’s strategic focus includes the careful selection and advancement of its drug candidates through rigorous clinical development. This approach is designed to address specific, high-need areas within oncology. The presentation will likely elaborate on the scientific rationale and clinical progress supporting these programs.
Context Therapeutics aims to distinguish itself by targeting novel mechanisms of action to combat difficult-to-treat cancers. Its efforts are aligned with the broader goal of improving patient outcomes in women's oncology. The conference offers a platform to articulate these long-term objectives to a global audience.
The upcoming presentation at the Jefferies Global Healthcare Conference offers a significant opportunity for Context Therapeutics to update the investment community. It highlights the company's dedicated efforts in advancing novel treatments for women's cancers through its targeted oncology programs. The detailed discussion of ONC-392 and CTX-177 underscores the company's strategic commitment to addressing unmet medical needs in this critical field.